title: Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
abstract: In patients with myelodysplastic syndromes (MDS) iron overload caused by long-term red blood cell transfusions is an important factor for comorbidity especially in low-risk MDS. In this report we present the results of a comparative study based on colony formation assays of hematopoietic cells in MDS patients with and without iron overload. We demonstrate that iron overload suppresses the proliferation of erythroid progenitors cells (BFU-E), while the myeloid compartment (CFU-GM) was not found to be affected. Even patients with slightly elevated ferritin values show an impaired proliferation capacity in comparison to patients with normal ferritin levels. Furthermore, we show that this negative impact is reversible by sufficient iron chelation therapy.
authors.affiliation: Department of Hematology and Oncology, Georg August University, Göttingen, Germany.
authors.forename: Julia
authors.initials: J
authors.lastname: Hartmann
authors.forename: Friederike
authors.initials: F
authors.lastname: Braulke
authors.forename: Ursula
authors.initials: U
authors.lastname: Sinzig
authors.forename: Gerald
authors.initials: G
authors.lastname: Wulf
authors.forename: Jens Holger
authors.initials: JH
authors.lastname: Maas
authors.forename: Frank
authors.initials: F
authors.lastname: Konietschke
authors.forename: Detlef
authors.initials: D
authors.lastname: Haase
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D002452:Cell Count; D049109:Cell Proliferation / Q000187:drug effects; D015331:Cohort Studies; D000077588:Deferasirox; D015672:Erythroid Precursor Cells / Q000473:pathology / Q000502:physiology*; D005260:Female; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology / Q000627:therapeutic use; D019190:Iron Overload / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications / Q000473:pathology*; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D000077588:Deferasirox